These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 276385

  • 1. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM, Lichinitser MR, Svet-Moldavskiĭ GIa, Mkheidze DM.
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Effect of deoxycytidine on the efficacy of cytosine arabinoside in BALB/C mice with Rauscher erythroblastic leukemia].
    Barkhotkina MF, Bukhman VM.
    Biull Eksp Biol Med; 1980 Oct; 90(10):472-3. PubMed ID: 7426711
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Single versus combination chemotherapy of L1210 leukemia.
    Koza I, Balázová E, Ujházy V.
    Neoplasma; 1980 Oct; 27(6):691-6. PubMed ID: 7254424
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
    Presant CA, Vietti TJ, Valeriote F, Coulter DM.
    J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
    [Abstract] [Full Text] [Related]

  • 8. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I, Hara M, Ohmoto E, Oda Y, Endo Y, Fujimoto S, Uchida K, Takaoka K, Watanabe S, Lai M, Kohi F, Kitajima K, Kimura I, Sanada H, Tokioka M, Adachi T, Yorimitsu S.
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
    Weil M, Auclerc MF, Schaison G, Auclerc G, Daubrisson A, Degos L, Caro J, Marty M, Jacquillat GI.
    Nouv Presse Med; 1982 Oct 09; 11(39):2911-4. PubMed ID: 6755389
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ, Karp JE, Vaughan WP.
    J Natl Cancer Inst; 1981 Sep 09; 67(3):529-38. PubMed ID: 6944525
    [Abstract] [Full Text] [Related]

  • 16. [Clinical use of cytosine arabinoside in infancy. I. Cytosine arabinoside in the treatment of acute leukosis].
    Masi M, Vivarelli F, Paolucci P, Vecchi V.
    Minerva Pediatr; 1975 Sep 15; 27(28):1539-50. PubMed ID: 1101022
    [No Abstract] [Full Text] [Related]

  • 17. Limited activity of ICRF-159 in advanced acute leukemia.
    Bakowski MT, Prentice HG, Lister TA, Malpas JS, McElwain TJ, Powles RL.
    Cancer Treat Rep; 1979 Jan 15; 63(1):127-9. PubMed ID: 369684
    [Abstract] [Full Text] [Related]

  • 18. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
    Kline I, Woodman RJ, Gang M, Sirica A, Venditti JM, Goldin A.
    Cancer Chemother Rep; 1972 Jun 15; 56(3):327-34. PubMed ID: 19051491
    [Abstract] [Full Text] [Related]

  • 19. Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.
    Schmid FA, Hutchison DJ, Otter GM, Stock CC.
    Cancer Treat Rep; 1976 Jan 15; 60(1):23-7. PubMed ID: 1000516
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
    Cass CE, Muzik H, Paterson AR.
    Cancer Res; 1975 May 15; 35(5):1187-93. PubMed ID: 1120308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.